This guidance clarifies the requirements for product name placement, size, prominence, and frequency in promotional labeling and advertisements for prescription drugs. The disclosure of the product name in promotional labeling and advertisements is important for proper identification and to ensure safe and effective use. This guidance also articulates the circumstances under which FDA intends to refrain from taking enforcement action regarding these requirements. We believe that following this guidance will allow for appropriate advertising and promotion without presenting any public health risk to patients.
Artigos recentes
- Accelerating Clinical Trials in the EU (ACT EU) .Delivering an EU clinical trials transformation initiative
- COMMISSION IMPLEMENTING DECISION (EU) 2022/6 of 4 January 2022 amending Implementing Decision (EU) 2021/1182
- Publicado Regulamento (UE) 2021/2282 do Parlamento Europeu e do Conselho relativo à avaliação das tecnologias da saúde
- Progressive roll-out of the In Vitro Diagnostic Medical Devices Regulation
- International regulators’ reflections on remote approaches to GCP and GMP regulatory oversight during COVID-19 pandemic
- EMA launches the Regulatory Science Research Needs initiative
- FDA final guidance on CMC postapproval changes for annual reports
- PESSOA RESPONSÁVEL de DISPOSITIVOS MÉDICOS : Uma formação muito esclarecedora e útil com uma excelente formadora